SEC Comment Letter for Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Nov 24, 2014
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Nov. 24, 2014 · CIK: 0000921114 · Accession: 0000000000-14-059855
AI Filing Summary & Sentiment
File numbers found in text: 000-23930
Letter
November 24, 2014 Via E -mail Jeremy Curnock Cook Interim Chief Executive Officer AmpliPhi Biosciences Corporation 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060
Re: AmpliPhi Biosciences Corporation Preliminary Proxy Statement on Schedule 14A Filed November 7, 2014 File No. 000-23930
Dear Mr. Cook :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
November 24, 2014 Via E -mail Jeremy Curnock Cook Interim Chief Executive Officer AmpliPhi Biosciences Corporation 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 Re: AmpliPhi Biosciences Corporation Preliminary Proxy Statement on Schedule 14A Filed November 7, 2014 File No. 000-23930 Dear Mr. Cook : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Riedler Assistant Director